Cognition Therapeutics (NASDAQ:CGTX) Receives “Buy” Rating from HC Wainwright

HC Wainwright reissued their buy rating on shares of Cognition Therapeutics (NASDAQ:CGTX) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright currently has a $3.00 target price on the stock.

Separately, Chardan Capital reduced their price objective on Cognition Therapeutics from $8.00 to $4.00 and set a “buy” rating for the company in a research report on Thursday, May 8th. One equities research analyst has rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $5.63.

Cognition Therapeutics Trading Up 8.2%

CGTX opened at $0.32 on Thursday. The business has a 50 day moving average of $0.33 and a 200-day moving average of $0.48. The stock has a market capitalization of $20.12 million, a price-to-earnings ratio of -0.44 and a beta of 0.75. Cognition Therapeutics has a 1-year low of $0.22 and a 1-year high of $2.54.

Cognition Therapeutics (NASDAQ:CGTX) last released its earnings results on Tuesday, May 6th. The company reported ($0.14) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.02). Equities analysts predict that Cognition Therapeutics will post -0.8 EPS for the current year.

Institutional Investors Weigh In On Cognition Therapeutics

Several large investors have recently made changes to their positions in the company. Two Sigma Investments LP lifted its holdings in Cognition Therapeutics by 372.2% during the 4th quarter. Two Sigma Investments LP now owns 53,691 shares of the company’s stock valued at $38,000 after purchasing an additional 42,321 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Cognition Therapeutics by 8.9% in the fourth quarter. Geode Capital Management LLC now owns 352,348 shares of the company’s stock valued at $247,000 after acquiring an additional 28,705 shares during the last quarter. Voss Capital LP acquired a new position in shares of Cognition Therapeutics in the 4th quarter worth approximately $351,000. Sigma Planning Corp boosted its holdings in shares of Cognition Therapeutics by 211.6% in the 4th quarter. Sigma Planning Corp now owns 614,490 shares of the company’s stock worth $431,000 after acquiring an additional 417,300 shares in the last quarter. Finally, BIOS Capital Management LP bought a new stake in Cognition Therapeutics during the 4th quarter worth approximately $4,208,000. Institutional investors own 43.35% of the company’s stock.

About Cognition Therapeutics

Cognition Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.